Convection-enhanced delivery in the treatment of malignant glioma

REFERENCES

• Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005; 109: 93–108
   PubMed Web of Science ®Google Scholar
• Central Brain Tumor Registry of the United States. Available at: http://www.cbtrus.org/2004-2005/tables/2005.table19.pdf accessed 15 October 2005
   Google Scholar
• Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42: 709–720
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076–2080
   PubMed Web of Science ®Google Scholar
• Broaddus WC, Prabhu SS, Gillies GT, et al. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg 1998; 88: 734–742
   PubMed Web of Science ®Google Scholar
• Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of admin-istration. Brain Res 2000; 856: 281–290
   PubMed Web of Science ®Google Scholar
• Kaiser MG, Parsa AT, Fine RL, et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000; 47: 1391 —1398
   Google Scholar
• Morrison PF, Chen MY, Chadwick RS, et al. Focal delivery during direct infusion to brain: Role of flow rate, catheter diameter, and tissue mechanics. Am JPhysiol 1999; 277: R1218—R1229
   Google Scholar
• Chen MY, Lonser RR, Morrison PF, et al. Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentra-tion, and tissue-cannula sealing time. J Neurosurg 1999; 90: 315–320
   PubMed Web of Science ®Google Scholar
• Croteau D, Walbridge S, Morrison PF, et al. Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg 2005; 102: 90–97
   PubMed Web of Science ®Google Scholar
• Lonser RR, Gogate N, Morrison PF. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 1998; 89: 616–622
   PubMed Web of Science ®Google Scholar
• Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: In vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002; 97: 905–913
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Pannu YS, Sung C, et al. Convective distribution of macromolecules in the primate brain demonstrated using compu-terized tomography and magnetic resonance imaging. J Neurosurg 2003; 98: 584–590
   PubMed Web of Science ®Google Scholar
• Sandberg DI, Edgar MA, Souweidane MM. Convection-enhanced delivery into the rat brainstem. J Neurosurg 2002; 96: 885–891
   PubMed Web of Science ®Google Scholar
• Prabhu SS, Broaddus WC, Gillies GT, et al. Distribution of macromolecular dyes in brain using positive pressure infusion: A model for direct controlled delivery of therapeutic agents. Surg Neurol 1998; 50: 367–375
   PubMed Web of Science ®Google Scholar
• Chen MY, Hoffer A, Morrison PF, et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg 2005; 103: 311–319
   PubMed Web of Science ®Google Scholar
• Boucher Y, Salehi H, Witwer B, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br] Cancer 1997; 75: 829–836
   PubMed Web of Science ®Google Scholar
• Vavra M, Ali MJ, Kang EW, et al. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro-oncol 2004; 6: 104–112
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: Symposium review. J Neurooncol 2005; 73: 57–69
   PubMed Web of Science ®Google Scholar
• Shih AH, Dai C, Hu X, et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64: 4783–4789
   PubMed Web of Science ®Google Scholar
• Uhrbom L, Hesselager G, Nister M, et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998; 58: 5275–5279
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd. Topotecan: Incorporating it into the treatment of solid tumors. Oncologist 1998; 3: 1–3
   PubMedGoogle Scholar
• Friedman HS, Kerby T, Fields S, et al. Topotecan treatment of adults with primary malignant glioma: The Brain Tumor Center at Duke. Cancer 1999; 85: 1160–1165
   PubMed Web of Science ®Google Scholar
• Bruce JN, Falavigna A, Johnson JP, et al. Intracerebral clysis in a rat glioma model. Neurosurgery 2000; 46: 683–691
   PubMed Web of Science ®Google Scholar
• Degen JW, Walbridge S, Vortmeyer AO, et al. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats.] Neurosurg 2003; 99: 893–898
   PubMed Web of Science ®Google Scholar
• Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004; 64: 6858–6862
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kawakami M, Kioi M, et al. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004; 101: 1004–1011
   PubMed Web of Science ®Google Scholar
• Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005; 12: 778–788
   PubMed Web of Science ®Google Scholar
• Cunningham J, Oiwa Y, Nagy D, et al. Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant 2000; 9: 585–594
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Mirek H, Berger MS, et al. Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J Neurosurg 2005; 102: 328–335
   PubMed Web of Science ®Google Scholar
• Barth RF, Wu G, Yang W, et al. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radiat 'sot 2004; 61: 899–903
   PubMed Web of Science ®Google Scholar
• Yang W, Barth RF, Wu G, et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat 'sot 2004; 61: 981–985
   PubMed Web of Science ®Google Scholar
• Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362–1368
   PubMed Web of Science ®Google Scholar
• Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral adminis-tration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000; 6: 2157–2165
   PubMed Web of Science ®Google Scholar
• Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (N BI-3001)for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003; 88: 93–103
   PubMedGoogle Scholar
• Kunwar S. Convection-enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88: 105–111
   PubMedGoogle Scholar
• Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65: 27–35
   PubMed Web of Science ®Google Scholar
• Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 2004; 100: 472–479
   PubMed Web of Science ®Google Scholar
• Pöpperl G, Goldbrunner R, Gildehaus FJ, et al. 042-8fifluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005; 32: 1018-1025
   Google Scholar
• Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003; 54: 479–487
   PubMed Web of Science ®Google Scholar
• Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 2005; 56: 1243–1252
   PubMed Web of Science ®Google Scholar
• Vogel TW, Bruce JN. Local delivery methods into the CNS. In: Proctor MR, Black PM, eds. Minimally Invasive Neurosurgery, Totowa, NJ, USA: Humana Press, 2005: pp. 297–316
   Google Scholar